The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Del PreteS.A., MaurerL.H., O'DonnellJ., ForcierR.J., LeMarbreP.Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep.1984; 68(11): 1403–1405.
2.
National Comprehensive Cancer Network. NCCN melanoma clinical practice guidelines version 1.2006. Available at: http://www.nccn.com/. Accessed on November 26, 2005.
3.
National Cancer Institute.Melanoma (PDQ) treatment, health professional version. Available at: http://www.cancer.gov/. Accessed on November 26, 2005.
4.
LiY., McClayE.F.Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol.2002; 29(5): 413–426.
5.
SerroneL., ZeuliM., SegaF.M., CognettiF.Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res.2000; 19(1): 21–34.
6.
McClayE.F., MastrangeloM.J., BelletR.E., BerdD.Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep.1987; 71(5): 465–469.
7.
RichardsJ.M., GilewskiT.A., RammingK., MitchelB., DoaneL.L., VogelzangN.J.Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer.1992; 69(2): 427–429.
8.
CrowellE.B., HigaG.M.The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen. W V Med J.1993; 89: 233–235.
9.
MiddletonM.R., LoriganP., OwenJ.. A randomized phase 3 study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interfer-on in advanced melanoma. Br J Cancer.2000; 82(6): 1158–1162.
10.
CreaganE.T., SumanV.J., DaltonR.J.. Phase 3 clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol.1999; 17(6): 1884–1890.
11.
ChapmanP.B., EinhornL.H., MeyersM.L.. Phase 3 multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol.1999; 17(9): 2745–2751.
12.
FisherR.I., NeifeldJ.P., LippmanM.E.Oestrogen receptors in human malignant melanoma. Lancet.1976; 2(7981): 337–339.
13.
RusthovenJ.J., QuirtI.C., IscoeN.A.. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol.1996; 14(7): 2083–2090.
14.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
15.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at: http://www.nccn.com/. Accessed on November 27, 2005.
16.
McClayE.F., MastrangeloM.J., BerdD., BelletR.E.Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer.1992; 50: 553–556.
17.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
18.
KintzelP.E.Anticancer drug-induced kidney disorders — incidence, prevention and management. Drug Saf.2001; 24(1): 19–38.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(Suppl 13): 10–17.
23.
OzerH., ArmitageJ.O., BennettC.L.. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–3585.
24.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
25.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
26.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
27.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
28.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Sourcebook.3rd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
29.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
